Friday February 15, 9:39 am Eastern
BioMS Medical Corp.
BioMS Medical Corp. (CDNX: MS - news), a leading developer in the treatment of multiple sclerosis, is very pleased to announce that it has received preliminary results regarding the Phase II MBP8298 human clinical trial on chronic progressive multiple sclerosis patients.
The placebo-controlled double-blind human clinical trial was conducted over a 42-month period on 32 patients at the University of Alberta. The Phase II trial involved the intravenous injection of MBP8298, the proprietary peptide technology licensed to BioMS Medical from the University of Alberta. Patients had levels of their anti-Myelin Basic Protein ("anti-MBP") antibodies in the cerebrospinal fluid measured, and were assessed as to clinical progression (or "decline") by such standard measures as the Expanded Disability Status Score ("EDSS") and the 22 meter Timed Walk. The trial was designed to identify a group of MS patients who showed complete or partial suppression of anti-MBP antibodies following injections of MBP8298, and to determine if this was related with any clinical stabilization.
The preliminary results indicate:
Full details of the Phase II trial will be released to BioMS Medical in the future, and the company will publicly release those results in keeping with the terms of the original licensing agreement with the University of Alberta.
Further analysis from Kevin Giese regarding the Phase II preliminary results can be heard on an audio archive on the company's web site at www.biomsmedical.com.
The Canadian Venture Exchange has
not reviewed and does not accept
responsibility for the adequacy or accuracy of this press release.
For further information
Ryan Giese, Corporate Communications,
BioMS Medical Corp. 780-413-7152, 780-466-6791 Fax
Jay Hussey, Investor Relations, The Equicom Group Inc. 416-815-0700 ext. 225, 416-815-0080 Fax
Copyright © 2002 Yahoo! Inc